Filing summary
Entity and period: The filing is for Apollo Medical Holdings, Inc., not a company named Astrana Health, Inc. It is a Form 10-K for the fiscal year ended January 31, 2014; the filing also gives quarterly results for the quarter ended that date. The company operated an integrated physician-led healthcare delivery business in California, serving Medicare, commercial and Medi-Cal patients.
Business context and developments
Apollo provided hospitalist and other physician services, managed affiliated medical groups and clinics, and operated an accountable care organization participating in Medicare’s Shared Savings Program. Its network included more than 700 physicians as of April 30, 2014. Growth during the year reflected new hospital contracts, expanded services, the Maverick Medical Group launch and three medical-clinic acquisitions. The company reported no Medicare Shared Savings Program revenue in either year.
Financial performance and position
| Metric | FY ended Jan. 31, 2014 | FY ended Jan. 31, 2013 |
|---|---|---|
| Net revenue | $10.48 million | $7.78 million |
| Cost of services | $9.08 million | $6.32 million |
| Gross profit / margin | $1.41 million / 13.4% | $1.46 million / 18.8% |
| Operating expenses | $5.32 million | $3.54 million |
| Operating loss | $3.91 million | $2.08 million |
| Net loss | $4.56 million | $8.90 million |
| Basic and diluted loss per share | $0.12 | $0.27 |
| Cash used in operations | $1.48 million | Cash provided: $58,000 |
| Cash and cash equivalents at year-end | $1.45 million | $1.18 million |
Revenue increased 34.8%, but cost of services rose faster, by 43.7%, and gross margin contracted. Higher physician costs, clinic and IPA growth, and ACO-related and administrative spending contributed to weaker operating results. Net loss narrowed largely because the prior-year period included a $5.85 million noncash loss on derivative liabilities; that loss did not recur, and interest expense also declined.
At year-end, total assets were $3.96 million, current liabilities were $4.55 million, and total liabilities were $5.65 million. Stockholders’ deficit was $1.69 million. Reported total debt was approximately $4.28 million, including $2.81 million drawn on NNA’s secured revolving facility, $1.10 million of convertible notes and other borrowings. Operating cash outflow and reliance on external financing are notable liquidity concerns. The filing reports no off-balance-sheet arrangements.
Material changes, outlook and risks
- Three payors together accounted for approximately 47.3% of revenue in FY2014; the filing also says three payors, including hospital contracts, represented approximately 48%. Hospital facility contracts generated approximately 81% of net revenue for hospitalist services.
- In December 2013, the NNA secured revolving facility was increased from $2 million to $4 million. It was due June 30, 2014 and secured by company and subsidiary assets. The company reported compliance with its financial covenants at January 31, 2014.
- After year-end, on March 28, 2014, Apollo entered into an NNA arrangement described as providing up to $12 million: a $2 million common-stock investment, $8 million in term and revolving loans, and a $2 million convertible-note commitment. The filing says the proceeds were intended to refinance existing debt and support working capital and acquisitions. The new credit facility included a $7 million term loan and a $1 million revolver, with repayment due by March 28, 2019.
- Management identified growth in coordinated, risk-based and value-based care as strategic opportunities, but gave no quantified financial guidance. Results depend on successful growth and integration, payer and hospital contracts, reimbursement levels, and management of medical costs under risk-sharing arrangements.
- Key risks include limited operating history, recurring losses and potential need for additional capital; concentrated payors and facility contracts; reimbursement and regulatory changes; risk-sharing losses; healthcare-law compliance; malpractice exposure; and competition for physicians. The company did not hold a limited Knox-Keene license, which it said could lead to regulatory action if authorities found its arrangements required one.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing three material weaknesses: undocumented control policies, insufficient segregation of accounting duties, and inadequate financial-reporting review and supervision. Management described remediation efforts. The independent auditor gave an unqualified opinion on the financial statements; its report did not attest to internal controls.
- Pending legal matters were described as ordinary-course matters, mainly malpractice claims. Management did not expect them to materially affect results, while acknowledging outcomes were uncertain and insurance might not cover all losses.
Most important facts for investors to verify
- Confirm the issuer identity and period: the supplied filing names Apollo Medical Holdings, Inc. and covers the year ended January 31, 2014, despite the request metadata naming Astrana Health, Inc. and “2013 Q4.”
- Review the March 2014 NNA financing documents and subsequent filings to confirm amounts funded, refinancing completed, maturity and covenant terms, collateral, and any dilution or control rights.
- Check liquidity, operating cash burn, debt maturities and access to additional capital, particularly given year-end current liabilities exceeded current assets.
- Assess whether revenue growth can translate into improved margins and cash generation, and monitor payor and hospital-contract concentration and risk-sharing medical costs.
- Track remediation of the disclosed material weaknesses and any subsequent changes in financial-reporting controls.